Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA)

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Berntson, Lillemor ^a   Nordal, Ellen ^b,c   Fasth, Anders ^d   Aalto, Kristiina ^e   Herlin, Troels ^f   Nielsen, Susan ^g   Rygg, Marite ^h,i   Zak, Marek ^g   Rönnelid, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g University of Copenhagen   (Denmark)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti CCP; Anti collagen type II antibodies; Arthritis; Child; Joints; Juvenile Idiopathic Arthritis; Rheumatoid factor

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COLLAGEN ANTIBODY; COLLAGEN TYPE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLLAGEN TYPE 2;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; JOINT DAMAGE; JUVENILE ARTHRITIS DAMAGE INDEX FOR ARTICULAR DAMAGE; JUVENILE RHEUMATOID ARTHRITIS; MALE; MUSCULOSKELETAL DISEASE; ONSET AGE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; ADULT; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; PROGNOSIS; SCANDINAVIA;

ADULT; AGE OF ONSET; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; MALE; PROGNOSIS; RHEUMATOID FACTOR; SCANDINAVIAN AND NORDIC COUNTRIES;

EID: 84902548672     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-22     Document Type: Article

References (35)

1. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011, 63(9):2809-2818. 10.1002/art.30426, 21560116.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Patricia W, . and International League of Associations for Rheumatology International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31(2):390-392. and International League of Associations for Rheumatology.
3. Modesto C, Anton J, Rodriguez B, Bou R, Arnal C, Ros J, Tena X, Rodrigo C, Rotes I, Hermosilla E, Barceló P. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol 2010, 39(6):472-479. 10.3109/03009741003742722, 20858139.
4. Berntson L, Andersson Gare B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, Marhaug G, Nielsen S, Pelkonen P, Rygg M. Incidence of juvenile idiopathic arthritis in the Nordic countries. a population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003, 30(10):2275-2282.
5. Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol 2008, 26(3):492-497.
6. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48(10):2741-2749. 10.1002/art.11223, 14558078.
7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbs K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581. 10.1002/art.27584, 20872595.
8. van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, Dijkmans B, van Venrooij WJ. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003, 30(4):825-828.
9. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61(7):608-611. 10.1136/ard.61.7.608, 1754144, 12079901.
10. Hromadnikova I, Stechova K, Pavla V, Hridelova D, Houbova B, Voslarova S, Nekvasilova H, Vavrinec J. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 2002, 35(6):397-401. 10.1080/0891693021000014970, 12568120.
11. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis 2007, 66(4):537-541. 1856042, 17040962.
12. Mullazehi M, Wick MC, Klareskog L, van Vollenhoven R, Rönnelid J. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res Ther 2012, 14(3):R100. 10.1186/ar3825, 3446477, 22548748.
13. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum 2006, 54(6):1759-1771. 10.1002/art.21892, 16736518.
14. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH, Cho CS, Kim HY. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000, 27(3):575-581.
15. Mottonen T, Hannonen P, Oka M, Rautiainen J, Jokinen I, Arvilommi H, Palosuo T, Aho K. Antibodies against native type II collagen do not precede the clinical onset of rheumatoid arthritis. Arthritis Rheum 1988, 31(6):776-779. 10.1002/art.1780310612, 3382450.
16. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P. Antibodies to type II collagen in early rheumatoid arthritis. correlation with disease progression. Arthritis Rheum 1996, 39(10):1720-1727. 10.1002/art.1780391015, 8843863.
17. Gilliam BE, Chauhan AK, Moore TL. Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2013, 11(1):31. 10.1186/1546-0096-11-31, 3765710, 23987731.
18. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31(11):2290-2294.
19. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, Rossi F, Bartoli M, Martini A, Ravelli A. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005, 52(7):2092-2102. 10.1002/art.21119, 15986372.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324. 10.1002/art.1780310302, 3358796.
21. Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, McNally B, Hill HR, Bohnsack J, Prahalad S. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2012, 10(1):29. 10.1186/1546-0096-10-29, 3490766, 22931121.
22. Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, Saribas S, Arisoy N, Kocazeybek B. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63(12):1687-1689. 10.1136/ard.2003.019331, 1754844, 15547097.
23. Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 2009, 47(12):1525-1530.
24. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002, 46(4):906-912. 10.1002/art.10167, 11953966.
25. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(5):677-680. 10.1093/rheumatology/keg184, 12709545.
26. Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, Emad Y. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 2013, 80(1):38-43. 10.1016/j.jbspin.2012.03.008, 22575064.
27. Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL. Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2011, 9:8. 10.1186/1546-0096-9-8, 3071779, 21439056.
28. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, Kim DL, Jones BM. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34(5):359-366. 10.1080/03009740510026634, 16234183.
29. Dewint P, Hoffman IE, Rogge S, Joos R, Union A, Dehoorne J, Delanghe J, Veys EM, De Keyser F, Elewaut D. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2006, 45(2):204-208.
30. Syed RH, Gilliam BE, Moore TL. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep 2008, 10(2):156-163. 10.1007/s11926-008-0027-4, 18460272.
31. Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64(12):1744-1749. 10.1136/ard.2004.033571, 1755292, 15843452.
32. Jonsson T, Arinbjarnarson S, Thorsteinsson J, Steinsson K, Geirsson AJ, Jonsson H, Valdimarsson H. Raised IgA rheumatoid factor (RF) but not IgM RF or IgG RF is associated with extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 1995, 24(6):372-375. 10.3109/03009749509095183, 8610222.
33. Jorgensen C, Legouffe MC, Bologna C, Brochier J, Sany J. IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp Rheumatol 1996, 14(3):301-304.
34. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007, 66(3):302-307. 10.1136/ard.2006.060608, 1856018, 17079248.
35. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Rönnelid J. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58(1):36-45. 10.1002/art.23188, 18163519.